Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding.
5-hydroxytryptophan
Parkinson's disease
apathy
depression
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
08
10
2019
revised:
05
02
2020
accepted:
13
02
2020
pubmed:
19
2
2020
medline:
12
6
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Several studies have indicated that altered serotonergic neurotransmission may contribute to non-motor features commonly associated with Parkinson's disease (PD) such as apathy and depression. 5-hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin. To date, there has been inconsistent research on the use of 5-HTP in PD. The purpose of this study was to compare the effects of 5-HTP with those of placebo on apathy and depressive symptoms in patients with PD. A single-center, randomized, double-blind placebo-controlled cross-over trial was employed; 25 individuals were subsequently enrolled into the study. Patients received placebo and 50 mg of 5-HTP daily over a period of 4 weeks. For the assessment of efficacy on depressive and apathy symptoms the Beck Depression Inventory-II (BDI-II), Hamilton Depression Rating Scale (HDRS) and Apathy Scale (AS) were respectively administered at screening, baseline and weeks 4, 8, 12 and 16. Primary efficacy outcomes were the comparison of 5-HTP to placebo in mean change from baseline to weeks 4, 8, 12 and 16 in total score on the AS, BDI-II and HDRS. Repeated-measures analysis revealed a significant improvement of depressive symptoms during the 50-mg 5-HTP treatment compared with placebo as assessed by the HDRS. No effect of 5-HTP was seen on apathy symptoms assessed by the AS. This study provides preliminary evidence of clinical benefit of 5-HTP for treating depressive symptoms in PD. Larger studies with a longer treatment duration are needed to corroborate these early findings.
Sections du résumé
BACKGROUND AND PURPOSE
Several studies have indicated that altered serotonergic neurotransmission may contribute to non-motor features commonly associated with Parkinson's disease (PD) such as apathy and depression. 5-hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin. To date, there has been inconsistent research on the use of 5-HTP in PD. The purpose of this study was to compare the effects of 5-HTP with those of placebo on apathy and depressive symptoms in patients with PD.
METHODS
A single-center, randomized, double-blind placebo-controlled cross-over trial was employed; 25 individuals were subsequently enrolled into the study. Patients received placebo and 50 mg of 5-HTP daily over a period of 4 weeks. For the assessment of efficacy on depressive and apathy symptoms the Beck Depression Inventory-II (BDI-II), Hamilton Depression Rating Scale (HDRS) and Apathy Scale (AS) were respectively administered at screening, baseline and weeks 4, 8, 12 and 16. Primary efficacy outcomes were the comparison of 5-HTP to placebo in mean change from baseline to weeks 4, 8, 12 and 16 in total score on the AS, BDI-II and HDRS.
RESULTS
Repeated-measures analysis revealed a significant improvement of depressive symptoms during the 50-mg 5-HTP treatment compared with placebo as assessed by the HDRS. No effect of 5-HTP was seen on apathy symptoms assessed by the AS.
CONCLUSIONS
This study provides preliminary evidence of clinical benefit of 5-HTP for treating depressive symptoms in PD. Larger studies with a longer treatment duration are needed to corroborate these early findings.
Substances chimiques
5-Hydroxytryptophan
C1LJO185Q9
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
779-786Informations de copyright
© 2020 European Academy of Neurology.
Références
Chaudhuri KR, Schapira AHV. Non-motor symptoms of PD diagnosis and management. Lancet Neurol 2006; 5: 235-245.
Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183-189.
Kostić VS, Djuričić BM, Čovičković-Šternić N, Bumbaširević L, Nikolić M, Mršulja BB. Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol 1987; 234: 94-96.
Politis M, Niccolini F. Serotonin in Parkinson's disease. Behav Brain Res 2015; 277: 136-145.
Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997; 17: 8451-8458.
Hashiguti H, Nakahara D, Maruyama W, Naoi M, Ikeda T. Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J Neural Transm 1993; 93: 213-223.
Kuhn DM, Arthur RE. L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein. Mol Brain Res 1999; 73: 78-84.
Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015; 30: 229-237.
Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641-1649.
Santangelo G, Barone P, Cuoco S, et al. Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. J Neurol 2014; 261: 2319-2328.
Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.
Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007; 22: 778-784.
Kulisevsky J, Pagonbarraga J, Pascual-Sedano B, García-Sánchez C, Gironell A. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008; 23: 1889-1896.
Thobois S, Lhommée E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136: 1568-1577.
Sierra M, Carnicella S, Strafella AP, et al. Apathy and impulse control disorders: Yin & yang of dopamine dependent behaviors. J Parkinsons Dis 2015; 5: 625-636.
Maillet A, Krack P, Lhommée E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. Brain 2016; 139: 2486-2502.
Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2015; 21: 833-842.
Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants - A review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22: 148-156.
Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701-707.
Funkiewiez A, Ardouin C, Caputo E, et al. Long term of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 834-839.
Kim HJ, Park SY, Cho YJ, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 2009; 287: 200-204.
Choi C, Sohn YH, Lee JH, Kim JS. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease. J Neurol Sci 2000; 172: 12-16.
Hamon M, Glowinski J. Regulation of serotonin synthesis. Life Sci 1974; 15: 1533-1548.
Aliño JJ, Gutierrez JL, Iglesias ML. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. Int Pharmacopsychiatry 1976; 11: 8-15.
Mendlewicz J, Youdim MBH. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord 1980; 2: 137-146.
Rousseau JJ. Effects of a levo-5-hydroxytryptophan-dihydroergocristine combination on depression and neuropsychic peformance: a double-blind placebo-controlled clinical trial in elderly patients. Clin Ther 1987; 9: 267-272.
Chou KL, Amick MM, Brandt J, et al. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010; 25: 2501-2507.
Appollonio I, Leone M, Isella V, et al. The frontal assessment battery (FAB): normative values in an Italian population sample. Neurol Sci 2005; 26: 108-116.
Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.
Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020-1028.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Revista Brasileira de Psiquiatria 2013; 35: 416-431.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134-139.
Leentjens AFG, Marsh L, Weintraub D, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 2004-2014.
Fahn S, Elton R. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Development in Parkinson's Disease, Vol.2. Florham Park: McMellam Health Care Information, 1987: 153-163.
Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 2006; 109: 325-338.
Albert PR, Vahid-Ansari F, Luckhart C. Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci 2014; 8: 199.
Ballanger B, Klinger H, Eche J, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord 2012; 27: 84-89.
Sharp SI, Ballard CG, Ziabreva I, et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2008; 26: 330-338.
Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50: 743-755.
Graham DG. Oxidative pathways for carecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978; 14: 633-643.
Stansley BJ, Yamamoto BK. Chronic L-Dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus. J Pharmacol Exp Ther 2014; 351: 440-447.
Navailles S, Bioulac B, Gross C, De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 2010; 38: 136-143.
Navailles S, Bioulac B, Gross C, De Deurwaerdère P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis 2011; 41: 585-590.
Kuhn DM, Arthur R Jr. Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J Neurosci 1998; 18: 7111-7117.
Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14: 518-531.
Muhammed K, Manohar S, Ben Yehuda M, et al. Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson's disease. Brain 2016; 139: 2706-2721.
Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077-1092.